Date: 2014-11-04
Type of information: R&D agreement
Compound: TGF-Beta therapeutics
Company: Oncodesign (France) Isarna Therapeutics (Germany)
Therapeutic area: Cancer - Oncology - Ophtalmological diseases - Fibrotic diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On November 4, 2014, Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, announced the signing of an agreement with Isarna Therapeutics. Oncodesign will conduct in vivo pharmacology studies to investigate the potential of TGF-β therapeutics that stimulate the human immune system to effectively fight cancer, ocular diseases and fibrosis. The total TGF-β therapeutics development program represents 1.75 M Euros of revenues for Oncodesign, of which 0.25 M Euros will be received for the third extension. The renewal extends the current agreement through the end of calendar year 2014 and includes Oncodesign scientific and technical support to Isarna Therapeutics’ oncology research.
Financial terms:
Latest news:
